**6. Conclusion**

In conclusion, the sophisticated array of radiopharmaceuticals that have been developed for imaging dementia using PET and SPECT scans is highlighted. Using such imaging techniques alone, or in combination with each other (and/or MRI, CT etc.), allows physicians to differentiate between related, and frequently clinically overlapping, disease entities with a high degree of diagnostic confidence. However, whilst [18F]FDG is readily

Diagnosis of Dementia Using Nuclear Medicine Imaging Modalities 223

Bierer, L. M., et al. (1995). Neurochemical correlates of dementia severity in Alzheimer's

Blin, J., et al. (1990). Positron emission tomography study in progressive supranuclear palsy.

Bohnen, N. I., et al. (2005). Cognitive correlates of alterations in acetylcholinesterase in

Brooks, D. J., et al. (1990). The relationship between locomotor disability, autonomic

by PET. *Brain*, Vol. 113, No. 5, (Oct. 1990), pp. 1539-1552, ISSN 0006-8950. Broussolle, E., et al. (1999). The relation of putamen and caudate nucleus 18F-dopa uptake to

Brucke, T., et al. (1997). Measurement of dopaminergic degeneration in Parkinson's disease

Brücke, T., et al. (2000). SPECT and PET imaging of the dopaminergic system in Parkinson's disease. *J. Neurol.*, Vol. 247, No. Suppl. 4, (Sep. 2000), pp. 2-7, ISSN 0340-5354 Brun, A., et al. (1994). Clinical and neuropathological criteria for frontotemporal dementia. *J.* 

Cagnin, A., et al. (2001). In-vivo measurement of activated microglia in dementia. *Lancet*,

Cagnin, A., et al. (2004). In vivo detection of microglial activation in frontotemporal dementia. *Ann. Neurol.*, Vol. 56, No. 6, (Dec. 2004), pp. 894-897, ISSN 0364-5134. Carome, M. and Wolfe, S. (2011). Florbetapir-PET imaging and postmortem β-amyloid

Castrejón, A. S., et al. (2005). 123-I Ioflupane (Datscan) presynaptic nigrostriatal imaging in

Choi, S. R., et al. (2009). Preclinical properties of 18F-AV-45: a PET agent for Aβ plaques in the brain. *J. Nucl. Med.*, Vol. 50, No. 11, (Nov. 2009), pp. 1887-1894, ISSN 0161-5505. Choi, S. R., et al. (2011). Correlation of Amyloid PET Ligand Florbetapir F 18 Binding with

Clark, C. M., et al. (2011a). Florbetapir-PET imaging and postmortem β-amyloid pathology. *J. Am. Med. Assoc.*, Vol. 305, No. 3, (Jan. 2011), pp. 1857-1858, ISSN 0098-7484. Clark, C. M., et al. (2011b). Use of Florbetapir-PET for Imaging ß-Amyloid Pathology. *J. Am. Med. Assoc.*, Vol. 305, No. 3, (Jan. 2011), pp. 275-283, ISSN 0098-7484.

241-251, ISSN 1750-3639.

0304-3940.

3050.

7484.

(Feb. 1995), pp. 749-760, ISSN 0022-3042.

47, No. 7, (Jul. 1990), pp. 747-752, ISSN 00039942.

No. 2, (Jul. 1999), pp. 141-151, ISSN 0022-510X.

Issue, (Oct. 2005), pp. 115-125, ISSN 1516-8913.

10.1097/WAD.1090b1013e31821300bc, ISSN 0893-0341.

*Transm.*, Vol. 50, No. Suppl., pp. 9-24, ISSN 0300-9564.

Vol. 358, No. 9280, (Aug. 2001), pp. 461-467, ISSN 0140-6736.

the derangement of neuronal function. *Brain Pathol.*, Vol. 1, No. 4, (Jul. 1991), pp.

disease: relative importance of the cholinergic deficits. *J. Neurochem.*, Vol. 64, No. 2,

Brain hypometabolic pattern and clinicometabolic correlations. *Arch. Neurol.*, Vol.

Alzheimer's disease *Neurosci. Lett.*, Vol. 380, No. 1-2, (May 2005), pp. 127-132, ISSN

dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure and Parkinson's disease studied

motor and cognitive performances in Parkinson's disease. *J. Neurol. Sci.*, Vol. 166,

with [123I]beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. *J. Neural* 

*Neurol. Neurosurg. Psychiatry*, Vol. 57, No. 4, (Apr. 1994), pp. 416-418, ISSN 0022-

pathology. *J. Am. Med. Assoc.*, Vol. 305, No. 18, (May 2011), pp. 1857, ISSN 0098-

patients with movement disorders. *Braz. Arch. Biol. Technol.*, Vol. 48, No. Special

Aß Aggregation and Neuritic Plaque Deposition in Postmortem Brain Tissue. *Alz. Dis. Assoc. Dis.*, Vol. 25, No. ASAP On-line, (Mar. 2011), pp. doi:

available, the more specialized radiopharmaceuticals described herein are still limited to sites typically possessing a cyclotron and advanced radiochemistry laboratories. In order for patients and physicians alike to benefit from these radiopharmaceuticals, global access has to be provided. The new partnerships growing between big pharma, small radiopharmaceutical companies, and larger companies possessing global radiopharmaceutical distribution networks, as well as the appearance of mobile scanner technology, should greatly facilitate access to nuclear medicine imaging in the next decade.
